Novo Nordisk A/S
Copenhagen : NOVO B

May 23, 2013 11:59 ET

Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg

BAGSVAERD, DENMARK--(Marketwired - May 23, 2013) - Company announcement No 39 2013:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Contact Information